News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
Operating Runway Extended to Mid-2020 Preparing to Submit NDA for Tenapanor in IBS-C in Early Q4 2018 Conference Call to be Held Today at 4:30 p.m. ET FREMONT, Calif. , Aug. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the second
View HTML
Toggle Summary Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
FREMONT, Calif. , Aug. 1, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018 . Management will host a conference call and webcast that afternoon at 4:30 p.m.
View HTML
Toggle Summary Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
FREMONT, Calif. , May 29, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will present a company overview at the Jefferies Global Healthcare Conference on Tuesday, June 5, 2018 at 2:30 p.m. ET in New York City .
View HTML
Toggle Summary Ardelyx Announces Pricing of Public Offering of Common Stock
FREMONT, Calif. , May 22, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $4.00 per share, before underwriting discounts and commissions, for gross proceeds of
View HTML
Toggle Summary Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
FREMONT, Calif. , May 21, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced it has entered into a $50.0 million senior secured term loan facility with Solar Capital Ltd. and the Life Sciences Group at Bridge Bank , a division of Western Alliance Bank .
View HTML
Toggle Summary Ardelyx Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , May 21, 2018 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), today announced that it has commenced an underwritten public offering of up to $50,000,000 of shares of its common stock. All of the shares to be sold in the offering will be offered by Ardelyx .
View HTML
Toggle Summary Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
On Track to Submit NDA for Tenapanor in IBS-C in Second Half of 2018 Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia FREMONT, Calif. , May 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the first
View HTML
Toggle Summary Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
License Agreement Advances First-in-Class Tenapanor for IBS-C and Hyperphosphatemia in Canada Ardelyx to Receive Up to CAD 25 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif. , March 19, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced a license agreement with
View HTML
Toggle Summary Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors
Enrollment Underway in Second Registration Study of Tenapanor for Hyperphosphatemia NDA for Tenapanor for IBS-C on Track for Submission in Second Half of 2018 FREMONT, Calif. , March 14, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today reported pipeline highlights and financial results for
View HTML
Toggle Summary Ardelyx Announces Departure of Chief Scientific Officer
FREMONT, Calif. , Feb. 12, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell , Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018 , to pursue a position as chief executive officer of an early stage biotech start-up company
View HTML